JP2011503044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503044A5 JP2011503044A5 JP2010532658A JP2010532658A JP2011503044A5 JP 2011503044 A5 JP2011503044 A5 JP 2011503044A5 JP 2010532658 A JP2010532658 A JP 2010532658A JP 2010532658 A JP2010532658 A JP 2010532658A JP 2011503044 A5 JP2011503044 A5 JP 2011503044A5
- Authority
- JP
- Japan
- Prior art keywords
- apomorphine
- poloxamer
- formulation according
- administration
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 229960004046 apomorphine Drugs 0.000 claims 12
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 11
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 8
- 229920001983 poloxamer Polymers 0.000 claims 6
- 229960000502 poloxamer Drugs 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 201000001881 impotence Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000013011 aqueous formulation Substances 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 229920001993 poloxamer 188 Polymers 0.000 claims 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 2
- 229920002507 Poloxamer 124 Polymers 0.000 claims 1
- 229920002511 Poloxamer 237 Polymers 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 claims 1
- 229940093448 poloxamer 124 Drugs 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07254426.5 | 2007-11-09 | ||
| EP07254426A EP2057982A1 (en) | 2007-11-09 | 2007-11-09 | Intranasal compositions |
| PCT/GB2008/003782 WO2009060226A1 (en) | 2007-11-09 | 2008-11-10 | Intranasal compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503044A JP2011503044A (ja) | 2011-01-27 |
| JP2011503044A5 true JP2011503044A5 (enExample) | 2011-12-22 |
| JP5530931B2 JP5530931B2 (ja) | 2014-06-25 |
Family
ID=39052379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532658A Expired - Fee Related JP5530931B2 (ja) | 2007-11-09 | 2008-11-10 | 鼻腔内組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8309108B2 (enExample) |
| EP (2) | EP2057982A1 (enExample) |
| JP (1) | JP5530931B2 (enExample) |
| KR (1) | KR101522529B1 (enExample) |
| CN (1) | CN101883555B (enExample) |
| AU (1) | AU2008326220B2 (enExample) |
| BR (1) | BRPI0819115A2 (enExample) |
| CA (1) | CA2705153C (enExample) |
| CY (1) | CY1113824T1 (enExample) |
| DK (1) | DK2214640T3 (enExample) |
| ES (1) | ES2398267T3 (enExample) |
| HR (1) | HRP20121036T1 (enExample) |
| MX (1) | MX2010005013A (enExample) |
| NZ (1) | NZ585107A (enExample) |
| PL (1) | PL2214640T3 (enExample) |
| PT (1) | PT2214640E (enExample) |
| SI (1) | SI2214640T1 (enExample) |
| TW (1) | TWI426928B (enExample) |
| WO (1) | WO2009060226A1 (enExample) |
| ZA (1) | ZA201003172B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP2545905A1 (en) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| EP2825159B1 (en) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| WO2013183055A1 (en) * | 2012-06-05 | 2013-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| JP6382187B2 (ja) | 2012-06-21 | 2018-08-29 | フォスフォレックス，インコーポレーテッド | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| GB201217419D0 (en) * | 2012-09-28 | 2012-11-14 | Innotesto Bvba | Improvements in or relating to oromucosal apomorphine compositions |
| EP3865120B1 (en) | 2013-07-19 | 2025-06-25 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| WO2021026421A1 (en) * | 2019-08-07 | 2021-02-11 | Aclipse One Inc. | Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
| GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
| CN115804754A (zh) * | 2022-12-16 | 2023-03-17 | 广州新济药业科技有限公司 | 吗啡鼻喷剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9103824D0 (en) * | 1991-02-23 | 1991-04-10 | Fisons Ag | Formulation |
| EP0689438B1 (en) * | 1993-03-26 | 2003-06-04 | Franciscus Wilhelmus Henricus Maria Merkus | Pharmaceutical compositions for intranasal administration of apomorphine |
| GB9416884D0 (en) | 1994-08-20 | 1994-10-12 | Danbiosyst Uk | Drug delivery compositions |
| EP0834308A1 (en) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
| GB9713980D0 (en) | 1997-07-03 | 1997-09-10 | Danbiosyst Uk | New conjugates |
| AU751182B2 (en) * | 1997-12-02 | 2002-08-08 | Archimedes Development Limited | Compositions for nasal administration |
| US6436950B1 (en) | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
-
2007
- 2007-11-09 EP EP07254426A patent/EP2057982A1/en not_active Withdrawn
-
2008
- 2008-11-07 TW TW097143029A patent/TWI426928B/zh not_active IP Right Cessation
- 2008-11-10 DK DK08847366.5T patent/DK2214640T3/da active
- 2008-11-10 MX MX2010005013A patent/MX2010005013A/es active IP Right Grant
- 2008-11-10 HR HRP20121036AT patent/HRP20121036T1/hr unknown
- 2008-11-10 BR BRPI0819115-8A patent/BRPI0819115A2/pt not_active IP Right Cessation
- 2008-11-10 JP JP2010532658A patent/JP5530931B2/ja not_active Expired - Fee Related
- 2008-11-10 NZ NZ585107A patent/NZ585107A/en not_active IP Right Cessation
- 2008-11-10 ES ES08847366T patent/ES2398267T3/es active Active
- 2008-11-10 CN CN200880115432XA patent/CN101883555B/zh not_active Expired - Fee Related
- 2008-11-10 CA CA2705153A patent/CA2705153C/en not_active Expired - Fee Related
- 2008-11-10 KR KR1020107011658A patent/KR101522529B1/ko not_active Expired - Fee Related
- 2008-11-10 AU AU2008326220A patent/AU2008326220B2/en not_active Ceased
- 2008-11-10 PT PT88473665T patent/PT2214640E/pt unknown
- 2008-11-10 PL PL08847366T patent/PL2214640T3/pl unknown
- 2008-11-10 WO PCT/GB2008/003782 patent/WO2009060226A1/en not_active Ceased
- 2008-11-10 US US12/741,932 patent/US8309108B2/en not_active Expired - Fee Related
- 2008-11-10 SI SI200830875T patent/SI2214640T1/sl unknown
- 2008-11-10 EP EP08847366A patent/EP2214640B1/en not_active Not-in-force
-
2010
- 2010-05-05 ZA ZA2010/03172A patent/ZA201003172B/en unknown
-
2013
- 2013-01-23 CY CY20131100059T patent/CY1113824T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503044A5 (enExample) | ||
| RU2470016C2 (ru) | Производное бипиразола | |
| TWI496594B (zh) | 噴灑用凝膠型皮膚及/或黏膜附著型製劑及使用該製劑之投藥系統 | |
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| ES2573414T3 (es) | Administración parenteral de tapentadol | |
| JP2005527535A5 (enExample) | ||
| MX2009009131A (es) | Mejoras en y con relacion a composiciones medicinales. | |
| EP2549988A1 (en) | Fast dissolving drug delivery systems | |
| JP2018513188A5 (enExample) | ||
| CN1222287C (zh) | 含有佐米曲普坦的药用制剂 | |
| US20110237563A1 (en) | Fast dissolving drug delivery systems | |
| JP2013541583A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2015524423A5 (enExample) | ||
| ES2544840T3 (es) | Clenbuterol para su uso en el tratamiento del autismo | |
| JP2011500589A5 (enExample) | ||
| WO2020030991A1 (en) | Dosage form for insertion into the mouth | |
| JP2016505050A5 (enExample) | ||
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| US20220387421A1 (en) | Drug products for intranasal administration and uses thereof | |
| JP2019516797A5 (enExample) | ||
| JP2009506043A5 (enExample) | ||
| ES2894330T3 (es) | Acido acetilsalicílico para uso en el tratamiento de la influenza de moderada a grave |